Trials / Completed
CompletedNCT03440515
Management of Imatinib-associated Severe Skin Rash in Patients With Gastrointestinal Stromal Tumor
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 29 (actual)
- Sponsor
- Asan Medical Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To achieve optimal clinical outcomes with imatinib in GIST patients, it is crucial to maintain standard imatinib dose. Skin rash is a relatively common and sometimes severe adverse event of imatinib in GIST patients and may affect imatinib compliance. Our previous retrospective study suggested that severe skin rash induced by imatinib can be managed by systemic steroid without imatinib dose interruption or reduction. This phase II study was conducted to evaluate the efficacy and safety of systemic steroid in GIST patients with imatinib-associated severe skin rash.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Prednisone | Prednisone treatment for severe skin rash induced by imatinib |
Timeline
- Start date
- 2014-08-01
- Primary completion
- 2017-06-01
- Completion
- 2017-06-01
- First posted
- 2018-02-22
- Last updated
- 2020-01-07
Source: ClinicalTrials.gov record NCT03440515. Inclusion in this directory is not an endorsement.